“In 2025, Mendus laid the foundation for its updated clinical strategy, aimed at capturing the full potential of vididencel as a post-remission immunotherapy in myeloid blood cancers. Because of its mode-of-action that is independent of specific mutations and thanks to a strong safety profile, vididencel can be positioned broadly across different subtypes of acute myeloid leukemia (AML) and in combination with different first-line therapies. Following positive phase 2 proof-of-concept data from the ADVANCE II trial, vididencel is currently being studied in the ongoing AMLM22-CADENCE trial as a combination treatment with oral azacitidine for patients in complete remission following intensive chemotherapy. To address the growing patient population treated with the less intensive combination of venetoclax and azacitidine, vididencel will be studied in the DIVA trial, which is currently in preparation to be ready for start mid-2026. Also anticipated in 2026 are the first-in-human data in chronic myeloid leukemia (CML), representing a significant expansion of the addressable patient population. The updated strategy follows the appointment of Prof Dr Tariq Mughal, an internationally acclaimed hemato-oncologist, as Chief Medical and Scientific Officer. Our manufacturing alliance with NorthX Biologics successfully delivered large-scale production of vididencel, as a key milestone for late-stage clinical development and future commercialization. Looking back on 2025, I am proud of our progress in developing vididencel as a robust product that can be manufactured at commercial scale, combined with an attractive clinical strategy that is supported by world-leading clinical experts.”

Erik Manting, Ph.D.
Chief Executive Officer

Mendus’ shareholders can request a printed copy of the Annual Report by contacting the company by e-mail, ir@mendus.com.